218 related articles for article (PubMed ID: 28355356)
1. Therapy of tacrolimus combined with corticosteroids in idiopathic membranous nephropathy.
Cui W; Lu X; Min X; Liu M; Guan S; Wang Y; Luo M; Li W; Li Q; Dong W; Miao L; Luo P
Braz J Med Biol Res; 2017 Mar; 50(4):e5976. PubMed ID: 28355356
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy.
Zou H; Jiang F; Xu G
Ren Fail; 2019 Nov; 41(1):673-681. PubMed ID: 31354007
[No Abstract] [Full Text] [Related]
3. Early initiation of tacrolimus or cyclophosphamide therapy for idiopathic membranous nephropathy with severe proteinuria.
Li X; Lv R; He Q; Li H; Du X; Lin W; Li Q; He X; Wang S; Chen J
J Nephrol; 2008; 21(4):584-91. PubMed ID: 18651550
[TBL] [Abstract][Full Text] [Related]
4. Treatment of idiopathic membranous nephropathy with combination of low-dose tacrolimus and corticosteroids.
He L; Peng Y; Liu H; Liu Y; Yuan S; Liu F; Yang D; Liu H; Chen X; Shao J; Fu M
J Nephrol; 2013; 26(3):564-71. PubMed ID: 22956434
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus combined with corticosteroids in treatment of nephrotic idiopathic membranous nephropathy: a multicenter randomized controlled trial.
Chen M; Li H; Li XY; Lu FM; Ni ZH; Xu FF; Li XW; Chen JH; Wang HY;
Am J Med Sci; 2010 Mar; 339(3):233-8. PubMed ID: 20220333
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy.
Liang Q; Li H; Xie X; Qu F; Li X; Chen J
Ren Fail; 2017 Nov; 39(1):512-518. PubMed ID: 28562168
[TBL] [Abstract][Full Text] [Related]
7. Tacrolimus combined with corticosteroids in idiopathic membranous nephropathy: a randomized, prospective, controlled trial.
Xu J; Zhang W; Xu Y; Shen P; Ren H; Wang W; Li X; Pan X; Chen N
Contrib Nephrol; 2013; 181():152-62. PubMed ID: 23689577
[TBL] [Abstract][Full Text] [Related]
8. Tacrolimus combined with corticosteroids versus Modified Ponticelli regimen in treatment of idiopathic membranous nephropathy: Randomized control trial.
Ramachandran R; Hn HK; Kumar V; Nada R; Yadav AK; Goyal A; Kumar V; Rathi M; Jha V; Gupta KL; Sakhuja V; Kohli HS
Nephrology (Carlton); 2016 Feb; 21(2):139-46. PubMed ID: 26205759
[TBL] [Abstract][Full Text] [Related]
9. Comparison of different therapies in high-risk patients with idiopathic membranous nephropathy.
Peng L; Wei SY; Li LT; He YX; Li B
J Formos Med Assoc; 2016 Jan; 115(1):11-8. PubMed ID: 26315481
[TBL] [Abstract][Full Text] [Related]
10. Retrospective analysis of tacrolimus combined with Tripterygium wilfordii polyglycoside for treating idiopathic membranous nephropathy.
Shang SL; Cai GY; Duan SW; Li P; Li QG; Chen XM
BMC Nephrol; 2018 Jul; 19(1):182. PubMed ID: 30021637
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of tacrolimus-based treatment for nephrotic idiopathic membranous nephropathy in young adults: A retrospective study.
Zhang XJ; Ji CF; Yuan JZ; Wang L; Zhang J; Fang W; Bai DF; Hu Z
Kaohsiung J Med Sci; 2019 Oct; 35(10):633-639. PubMed ID: 31225949
[TBL] [Abstract][Full Text] [Related]
12. Effective treatment administration of cyclophosphamide in membranous nephropathy.
Dede F; Ayili D; Sahiner S
J Nephrol; 2008; 21(4):560-5. PubMed ID: 18651546
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of cyclophosphamide or tacrolimus therapy for idiopathic membranous nephropathy.
Zou H; Jiang F; Xu G
Intern Med J; 2020 May; 50(5):612-619. PubMed ID: 31389094
[TBL] [Abstract][Full Text] [Related]
14. Effect of prolonged tacrolimus treatment in idiopathic membranous nephropathy with nephrotic syndrome.
Yuan H; Liu N; Sun GD; Jia Y; Luo P; Miao LN
Pharmacology; 2013; 91(5-6):259-66. PubMed ID: 23652322
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of tacrolimus combined with corticosteroids in patients with idiopathic membranous nephropathy: a systematic review and meta-analysis of randomized controlled trials.
Tian Z; Li Y; Xie Y; Yang Y; Xu J
Int Urol Nephrol; 2022 Oct; 54(10):2555-2566. PubMed ID: 35277831
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of tacrolimus monotherapy versus cyclophosphamide-corticosteroid combination therapy for idiopathic membranous nephropathy: A meta-analysis.
Gong L; Xu M; Xu W; Tang W; Lu J; Jiang W; Xie F; Ding L; Qian X
Medicine (Baltimore); 2021 Jul; 100(28):e26628. PubMed ID: 34260552
[TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy and safety of different tacrolimus concentrations for the treatment of patients with idiopathic membranous nephropathy.
Wang Q; Li M; Cheng X; Xu G
Sci Rep; 2021 Jun; 11(1):13274. PubMed ID: 34168218
[TBL] [Abstract][Full Text] [Related]
18. Comparison of tripterygium wilfordii multiglycosides and tacrolimus in the treatment of idiopathic membranous nephropathy: a prospective cohort study.
Liu S; Li X; Li H; Liang Q; Chen J; Chen J
BMC Nephrol; 2015 Dec; 16():200. PubMed ID: 26637482
[TBL] [Abstract][Full Text] [Related]
19. Clinical Predictors of Response to Prednisone Plus Cyclophosphamide in Patients with Idiopathic Membranous Nephropathy.
Li S; Wang L; Zhang M; Zhou W; Fang W; Wang Q; Qi C; Mou S; Shao X; Ni Z
Nephron; 2017; 135(2):87-96. PubMed ID: 27974710
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of tacrolimus vs cyclophosphamide in the therapy of patients with idiopathic membranous nephropathy: a meta-analysis.
Lin W; Li HY; Lin S; Zhou T
Drug Des Devel Ther; 2019; 13():2179-2186. PubMed ID: 31308629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]